"Thiazolidinediones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
THIAZOLES with two keto oxygens. Members are insulin-sensitizing agents which overcome INSULIN RESISTANCE by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma).
| Descriptor ID |
D045162
|
| MeSH Number(s) |
D02.886.675.933 D03.383.129.708.933
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thiazolidinediones".
Below are MeSH descriptors whose meaning is more specific than "Thiazolidinediones".
This graph shows the total number of publications written about "Thiazolidinediones" by people in this website by year, and whether "Thiazolidinediones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 2 | 0 | 2 |
| 1998 | 4 | 0 | 4 |
| 1999 | 2 | 0 | 2 |
| 2000 | 2 | 0 | 2 |
| 2001 | 3 | 0 | 3 |
| 2002 | 1 | 0 | 1 |
| 2003 | 3 | 1 | 4 |
| 2004 | 1 | 2 | 3 |
| 2005 | 3 | 2 | 5 |
| 2006 | 3 | 1 | 4 |
| 2007 | 1 | 3 | 4 |
| 2008 | 2 | 2 | 4 |
| 2009 | 2 | 2 | 4 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 0 | 2 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 2 | 3 |
| 2016 | 2 | 0 | 2 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thiazolidinediones" by people in Profiles.
-
Effect of thiazolidinedione therapy on the risk of uric acid stones. Kidney Int. 2019 05; 95(5):1022-1024.
-
A blockade of PI3K? signaling effectively mitigates angiotensin II-induced renal injury and fibrosis in a mouse model. Sci Rep. 2018 Jul 20; 8(1):10988.
-
Peroxisome Proliferator-activated Receptor-? Activation Augments the ß-Cell Unfolded Protein Response and Rescues Early Glycemic Deterioration and ß Cell Death in Non-obese Diabetic Mice. J Biol Chem. 2016 Oct 21; 291(43):22524-22533.
-
Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. Dig Dis Sci. 2016 May; 61(5):1387-97.
-
Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs. J Manag Care Spec Pharm. 2015 Dec; 21(12):1214-34.
-
Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015 Jun 09; 313(22):2263-73.
-
S-nitrosoglutathione reductase-dependent PPAR? denitrosylation participates in MSC-derived adipogenesis and osteogenesis. J Clin Invest. 2015 Apr; 125(4):1679-91.
-
Inhibition of cancer cell proliferation by PPAR? is mediated by a metabolic switch that increases reactive oxygen species levels. Cell Metab. 2014 Oct 07; 20(4):650-61.
-
Sirt1 and Sirt6 mediate beneficial effects of rosiglitazone on hepatic lipid accumulation. PLoS One. 2014; 9(8):e105456.
-
Enhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin. PLoS One. 2013; 8(6):e65777.